Jacket
发表于 2025-3-25 06:51:22
Mesothelial and Mesothelioma Cell LinesBC patients that express programmed cell death protein-1 (PD-1) in combination with chemotherapy in the first-line setting. ICIs are also being investigated in the neoadjuvant and adjuvant settings for TNBC. This chapter aims to discuss different ICIs used to treat all TNBC stages to date.
制度
发表于 2025-3-25 08:17:55
http://reply.papertrans.cn/20/1906/190570/190570_22.png
消音器
发表于 2025-3-25 14:07:54
http://reply.papertrans.cn/20/1906/190570/190570_23.png
滑动
发表于 2025-3-25 17:52:11
http://reply.papertrans.cn/20/1906/190570/190570_24.png
Afflict
发表于 2025-3-25 22:42:38
Growth Factors and Malignant Mesotheliomaincluding their mechanisms of action, efficacy, and tolerability. Moreover, we have also discussed their therapeutic potential based on combinatorial approaches with other targeted therapies in early and metastatic TNBC.
美色花钱
发表于 2025-3-26 02:46:21
,Antibody–Drug Conjugates: A New Therapeutic Approach for Triple-Negative Breast Cancer,including their mechanisms of action, efficacy, and tolerability. Moreover, we have also discussed their therapeutic potential based on combinatorial approaches with other targeted therapies in early and metastatic TNBC.
有常识
发表于 2025-3-26 07:53:47
Book 2023at enable us to better select personalized approaches in breast cancer management..The closing chapters deal with the challenges of conducting research in the era of precision medicine forcancer. The book is edited and authored by leading experts in this field and will be of interest for clinicians and scientists alike..
AGONY
发表于 2025-3-26 10:12:17
Novel Therapies on the Horizon,ing whether surgery can be omitted in patients who achieve a complete pathological response. In this chapter, I will review the impact of PST on surgical de-escalation and the data supporting the safety of this approach.
暂时休息
发表于 2025-3-26 16:06:13
http://reply.papertrans.cn/20/1906/190570/190570_29.png
巧思
发表于 2025-3-26 18:21:37
http://reply.papertrans.cn/20/1906/190570/190570_30.png